KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance of Gln metabolism-related genes in AML for potential biomarker identification.
- Researchers noticed that 8 Gln metabolism-related genes can serve as potential biomarkers for prognostic risk stratification in AML.
Acute myeloid leukemia (AML) is a genetically heterogeneous disease in which glutamine (Gln) plays a crucial role in driving its progression.
Jie Zhou and the team aimed to identify potential prognostic biomarkers for AML by analyzing Gln metabolism-related genes. By examining the connection between these genes and patient outcomes, the research sought to deepen the understanding of AML’s molecular pathways and improve risk stratification.
They performed an inclusive analysis of Gln-related genes that were differentially expressed between Cancer Genome Atlas-based patients with AML and normal samples using the limma package. Univariate analysis, least absolute shrinkage and selection operator (LASSO), and stepwise Cox regression were applied to identify prognostic gene signatures.
Risk score-based prognostic models and nomograms were developed to predict the prognostic risk for patients with AML. Consistent cluster analysis was conducted to stratify patients into distinct subtypes, and subtype-specific genes were identified using weighted gene co-expression network analysis (WGCNA).
About 8 potential prognostic biomarkers for AML were identified through a series of regression analyses, including HGF, ANGPTL3, MB, F2, CALR, EIF4EBP1, EPHX1, and PDHA1. Prognostic and nomogram models based on these genes demonstrated a clear distinction between high- and low-risk patients with AML.
The 8-gene signature effectively stratified patients into 2 subtypes, with Cluster 2 being more susceptible to a higher risk of poor AML prognosis. These 2 clusters also displayed distinct immune profiles. Among the subtype-related module genes, members of the HOXA and HOXB gene families appeared to be key genetic features of AML subtypes.
The study concluded that 8 Gln metabolism-related genes were identified as potential biomarkers for predicting prognostic risk in AML. These genes allowed for the effective stratification of molecular subtypes, enabling more precise prognostic risk categorization among patients.
This study was funded by the Scientific Research Project Program of the Sichuan Medical Association (No.S20038), Incubating Project of Deyang People’s Hospital (No.FHT202004).
Source: https://pubmed.ncbi.nlm.nih.gov/39300580/
Zhou J, Zhang N, Zuo Y, et al. (2024). “Glutamine metabolism-related genes predict the prognostic risk of acute myeloid leukemia and stratify patients by subtype analysis.” Hereditas. 2024;161(1):35. Published 2024 Sep 19. doi:10.1186/s41065-024-00338-8
